# An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)

Study · id `cardio:ct-nct01670981` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01670981](<https://clinicaltrials.gov/study/NCT01670981>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01670981

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 114 participants.

## Technical summary

Registry record NCT01670981. Randomized; quadruple masking; primary purpose treatment. Start 2013-02-20 (actual); primary completion 2016-02-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 114 participants (enrolled count; ClinicalTrials.gov record NCT01670981, source copy `cardio:ctgov-nct01670981-2021-05-27`, retrieved 2026-10-26)
- Started: 2013-02-20 (actual) (ClinicalTrials.gov record NCT01670981, source copy `cardio:ctgov-nct01670981-2021-05-27`, retrieved 2026-10-26)
- Primary completion: 2016-02-01 (actual) (ClinicalTrials.gov record NCT01670981, source copy `cardio:ctgov-nct01670981-2021-05-27`, retrieved 2026-10-26)
- Completion: 2018-03-07 (actual) (ClinicalTrials.gov record NCT01670981, source copy `cardio:ctgov-nct01670981-2021-05-27`, retrieved 2026-10-26)
- Countries: United States; Canada (ClinicalTrials.gov record NCT01670981, source copy `cardio:ctgov-nct01670981-2021-05-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01670981-2021-05-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)
- Acronym: ixCELLDCM
- Condition: Ischemic Dilated Cardiomyopathy (IDCM)
- Intervention (Biological): ixmyelocel-T
- Intervention (Other): Placebo
- Lead sponsor: Vericel Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial (`cardio:pubmed-27059887`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a753ef5ebb77da9dc13149174d3180cda5f7a4899c72b72831a75726920f0fb4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
